Scotia Capital Inc. Acquires New Holdings in Enovis Co. (NYSE:ENOV)

Scotia Capital Inc. acquired a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,632 shares of the company's stock, valued at approximately $598,000.

Several other hedge funds have also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new position in shares of Enovis during the fourth quarter valued at about $29,000. Quadrant Capital Group LLC increased its stake in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after purchasing an additional 239 shares during the period. UMB Bank n.a. lifted its position in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after buying an additional 484 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of Enovis in a report on Wednesday, April 9th.

Enovis Stock Up 2.4 %

Shares of ENOV stock traded up $0.75 during trading hours on Friday, hitting $31.91. 704,815 shares of the company's stock traded hands, compared to its average volume of 741,741. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $56.89. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.57 and a beta of 1.86. The stock's fifty day simple moving average is $37.53 and its two-hundred day simple moving average is $42.19.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. On average, analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.